Related Experiment Video
Updated: Jul 10, 2026

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
Published on: October 1, 2015
Treatment of chronic hepatitis C with recombinant interferon alfa-2b for nine months
1Gastroenterology Unit, Hospital Central de Asturias, School of Medicine, Oviedo, Spain.
Abstract:
This randomised, controlled trial was designed to assess the response to a nine month course of interferon (IFN) alfa-2b, starting with a higher than usual dose. Forty eight patients received IFN 5 million units (MU) three times a week for eight weeks followed by 3 MU three times weekly for seven months; 25 patients in the control group received no treatment. The overall response to treatment was 68.7%, an improvement over other studies, but the high rate of relapse (85% in patients who responded) suggested that a nine month treatment period was insufficient in most cases. Histological improvement was seen in more than 80% of responders to interferon, including a reduction in inflammatory activity, necrosis, and fibrosis.
Related Concept Videos
Retrovirus Life Cycles
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Hepatitis
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction

